p-Coumaric acid loaded into liquid crystalline systems as a novel strategy to the treatment of vulvovaginal candidiasis
Autor(a) principal: | |
---|---|
Data de Publicação: | 2021 |
Outros Autores: | , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UNESP |
Texto Completo: | http://dx.doi.org/10.1016/j.ijpharm.2021.120658 http://hdl.handle.net/11449/207737 |
Resumo: | Vulvovaginal candidiasis (VVC) is an extremely common type of vaginal infection, which is mainly caused by Candida albicans. However, non-albicans Candida species are frequently more resistant to conventional antifungal agents and can represent up to 30% of cases. Due to side effects and increasing antifungal resistance presented by standard therapies, phenolic compounds, such as p-coumaric acid (p-CA), have been studied as molecules from natural sources with potential antifungal activity. p-CA is a poorly water-soluble compound, thus loading it into liquid crystals (LCs) may increase its solubility and effectiveness on the vaginal mucosa. Thereby, here we propose the development of mucoadhesive liquid crystalline systems with controlled release of p-CA, for the local treatment of VVC. Developed LCs consisted of fixed oily and aqueous phases (oleic acid and cholesterol (5:1) and poloxamer dispersion 16%, respectively), changing only the surfactant phase components (triethanolamine oleate (TEA-Oleate) or triethanolamine (TEA), the latter producing TEA-Oleate molecules when mixed with oleic acid). Systems were also diluted in artificial vaginal mucus (1:1 ratio) to mimic the vaginal environment and verify possible structural changes on formulations upon exposure to the mucosa. From the characterization assays, p-CA loaded TEA-Oleate systems presented mucoadhesive profile, liquid crystalline mesophases, well-organized structures and pseudoplastic behaviour, which are desirable parameters for topical formulations. Moreover, they were able to control the release of p-CA throughout the 12 h assay, as well as decrease its permeation into the vaginal mucosa. p-CA showed antifungal activity in vitro against reference strains of C. albicans (SC5314), C. glabrata (ATCC 2001) and C. krusei (ATCC 6258), and exhibited higher eradication of mature biofilms than amphotericin B and fluconazole. In vivo experiments demonstrated that the formulations reduced the presence of filamentous forms in the vaginal lavages and provided an improvement in swelling and redness present in the mice vaginal regions. Altogether, here we demonstrated the potential and feasibility of using p-CA loaded liquid crystalline systems as a mucoadhesive drug delivery system for topical treatment of VVC. |
id |
UNSP_1d2793f27f53c21a085247d28db8f5aa |
---|---|
oai_identifier_str |
oai:repositorio.unesp.br:11449/207737 |
network_acronym_str |
UNSP |
network_name_str |
Repositório Institucional da UNESP |
repository_id_str |
2946 |
spelling |
p-Coumaric acid loaded into liquid crystalline systems as a novel strategy to the treatment of vulvovaginal candidiasisAnd biofilmCandida albicansCandida glabrataLiquid crystalline systemsP-coumaric acidVulvovaginal candidiasisVulvovaginal candidiasis (VVC) is an extremely common type of vaginal infection, which is mainly caused by Candida albicans. However, non-albicans Candida species are frequently more resistant to conventional antifungal agents and can represent up to 30% of cases. Due to side effects and increasing antifungal resistance presented by standard therapies, phenolic compounds, such as p-coumaric acid (p-CA), have been studied as molecules from natural sources with potential antifungal activity. p-CA is a poorly water-soluble compound, thus loading it into liquid crystals (LCs) may increase its solubility and effectiveness on the vaginal mucosa. Thereby, here we propose the development of mucoadhesive liquid crystalline systems with controlled release of p-CA, for the local treatment of VVC. Developed LCs consisted of fixed oily and aqueous phases (oleic acid and cholesterol (5:1) and poloxamer dispersion 16%, respectively), changing only the surfactant phase components (triethanolamine oleate (TEA-Oleate) or triethanolamine (TEA), the latter producing TEA-Oleate molecules when mixed with oleic acid). Systems were also diluted in artificial vaginal mucus (1:1 ratio) to mimic the vaginal environment and verify possible structural changes on formulations upon exposure to the mucosa. From the characterization assays, p-CA loaded TEA-Oleate systems presented mucoadhesive profile, liquid crystalline mesophases, well-organized structures and pseudoplastic behaviour, which are desirable parameters for topical formulations. Moreover, they were able to control the release of p-CA throughout the 12 h assay, as well as decrease its permeation into the vaginal mucosa. p-CA showed antifungal activity in vitro against reference strains of C. albicans (SC5314), C. glabrata (ATCC 2001) and C. krusei (ATCC 6258), and exhibited higher eradication of mature biofilms than amphotericin B and fluconazole. In vivo experiments demonstrated that the formulations reduced the presence of filamentous forms in the vaginal lavages and provided an improvement in swelling and redness present in the mice vaginal regions. Altogether, here we demonstrated the potential and feasibility of using p-CA loaded liquid crystalline systems as a mucoadhesive drug delivery system for topical treatment of VVC.Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)Department of Drugs and Medicines School of Pharmaceutical Sciences São Paulo State University (UNESP)Department of Biological Sciences School of Pharmaceutical Sciences São Paulo State University (UNESP)Laboratory of Molecular Cell Biology Institute of Botany and Microbiology KU LeuvenVIB-KU Leuven Center for MicrobiologyDepartment of Drugs and Medicines School of Pharmaceutical Sciences São Paulo State University (UNESP)Department of Biological Sciences School of Pharmaceutical Sciences São Paulo State University (UNESP)Universidade Estadual Paulista (Unesp)KU LeuvenVIB-KU Leuven Center for MicrobiologyFerreira, P. S. [UNESP]Victorelli, F. D. [UNESP]Rodero, C. F. [UNESP]Fortunato, G. C. [UNESP]Araújo, V. H.S. [UNESP]Fonseca-Santos, B. [UNESP]Bauab, T. M. [UNESP]Van Dijck, P.Chorilli, M. [UNESP]2021-06-25T11:00:10Z2021-06-25T11:00:10Z2021-06-15info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articlehttp://dx.doi.org/10.1016/j.ijpharm.2021.120658International Journal of Pharmaceutics, v. 603.1873-34760378-5173http://hdl.handle.net/11449/20773710.1016/j.ijpharm.2021.1206582-s2.0-85105870194Scopusreponame:Repositório Institucional da UNESPinstname:Universidade Estadual Paulista (UNESP)instacron:UNESPengInternational Journal of Pharmaceuticsinfo:eu-repo/semantics/openAccess2024-06-24T13:46:34Zoai:repositorio.unesp.br:11449/207737Repositório InstitucionalPUBhttp://repositorio.unesp.br/oai/requestopendoar:29462024-08-05T23:46:22.537634Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)false |
dc.title.none.fl_str_mv |
p-Coumaric acid loaded into liquid crystalline systems as a novel strategy to the treatment of vulvovaginal candidiasis |
title |
p-Coumaric acid loaded into liquid crystalline systems as a novel strategy to the treatment of vulvovaginal candidiasis |
spellingShingle |
p-Coumaric acid loaded into liquid crystalline systems as a novel strategy to the treatment of vulvovaginal candidiasis Ferreira, P. S. [UNESP] And biofilm Candida albicans Candida glabrata Liquid crystalline systems P-coumaric acid Vulvovaginal candidiasis |
title_short |
p-Coumaric acid loaded into liquid crystalline systems as a novel strategy to the treatment of vulvovaginal candidiasis |
title_full |
p-Coumaric acid loaded into liquid crystalline systems as a novel strategy to the treatment of vulvovaginal candidiasis |
title_fullStr |
p-Coumaric acid loaded into liquid crystalline systems as a novel strategy to the treatment of vulvovaginal candidiasis |
title_full_unstemmed |
p-Coumaric acid loaded into liquid crystalline systems as a novel strategy to the treatment of vulvovaginal candidiasis |
title_sort |
p-Coumaric acid loaded into liquid crystalline systems as a novel strategy to the treatment of vulvovaginal candidiasis |
author |
Ferreira, P. S. [UNESP] |
author_facet |
Ferreira, P. S. [UNESP] Victorelli, F. D. [UNESP] Rodero, C. F. [UNESP] Fortunato, G. C. [UNESP] Araújo, V. H.S. [UNESP] Fonseca-Santos, B. [UNESP] Bauab, T. M. [UNESP] Van Dijck, P. Chorilli, M. [UNESP] |
author_role |
author |
author2 |
Victorelli, F. D. [UNESP] Rodero, C. F. [UNESP] Fortunato, G. C. [UNESP] Araújo, V. H.S. [UNESP] Fonseca-Santos, B. [UNESP] Bauab, T. M. [UNESP] Van Dijck, P. Chorilli, M. [UNESP] |
author2_role |
author author author author author author author author |
dc.contributor.none.fl_str_mv |
Universidade Estadual Paulista (Unesp) KU Leuven VIB-KU Leuven Center for Microbiology |
dc.contributor.author.fl_str_mv |
Ferreira, P. S. [UNESP] Victorelli, F. D. [UNESP] Rodero, C. F. [UNESP] Fortunato, G. C. [UNESP] Araújo, V. H.S. [UNESP] Fonseca-Santos, B. [UNESP] Bauab, T. M. [UNESP] Van Dijck, P. Chorilli, M. [UNESP] |
dc.subject.por.fl_str_mv |
And biofilm Candida albicans Candida glabrata Liquid crystalline systems P-coumaric acid Vulvovaginal candidiasis |
topic |
And biofilm Candida albicans Candida glabrata Liquid crystalline systems P-coumaric acid Vulvovaginal candidiasis |
description |
Vulvovaginal candidiasis (VVC) is an extremely common type of vaginal infection, which is mainly caused by Candida albicans. However, non-albicans Candida species are frequently more resistant to conventional antifungal agents and can represent up to 30% of cases. Due to side effects and increasing antifungal resistance presented by standard therapies, phenolic compounds, such as p-coumaric acid (p-CA), have been studied as molecules from natural sources with potential antifungal activity. p-CA is a poorly water-soluble compound, thus loading it into liquid crystals (LCs) may increase its solubility and effectiveness on the vaginal mucosa. Thereby, here we propose the development of mucoadhesive liquid crystalline systems with controlled release of p-CA, for the local treatment of VVC. Developed LCs consisted of fixed oily and aqueous phases (oleic acid and cholesterol (5:1) and poloxamer dispersion 16%, respectively), changing only the surfactant phase components (triethanolamine oleate (TEA-Oleate) or triethanolamine (TEA), the latter producing TEA-Oleate molecules when mixed with oleic acid). Systems were also diluted in artificial vaginal mucus (1:1 ratio) to mimic the vaginal environment and verify possible structural changes on formulations upon exposure to the mucosa. From the characterization assays, p-CA loaded TEA-Oleate systems presented mucoadhesive profile, liquid crystalline mesophases, well-organized structures and pseudoplastic behaviour, which are desirable parameters for topical formulations. Moreover, they were able to control the release of p-CA throughout the 12 h assay, as well as decrease its permeation into the vaginal mucosa. p-CA showed antifungal activity in vitro against reference strains of C. albicans (SC5314), C. glabrata (ATCC 2001) and C. krusei (ATCC 6258), and exhibited higher eradication of mature biofilms than amphotericin B and fluconazole. In vivo experiments demonstrated that the formulations reduced the presence of filamentous forms in the vaginal lavages and provided an improvement in swelling and redness present in the mice vaginal regions. Altogether, here we demonstrated the potential and feasibility of using p-CA loaded liquid crystalline systems as a mucoadhesive drug delivery system for topical treatment of VVC. |
publishDate |
2021 |
dc.date.none.fl_str_mv |
2021-06-25T11:00:10Z 2021-06-25T11:00:10Z 2021-06-15 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://dx.doi.org/10.1016/j.ijpharm.2021.120658 International Journal of Pharmaceutics, v. 603. 1873-3476 0378-5173 http://hdl.handle.net/11449/207737 10.1016/j.ijpharm.2021.120658 2-s2.0-85105870194 |
url |
http://dx.doi.org/10.1016/j.ijpharm.2021.120658 http://hdl.handle.net/11449/207737 |
identifier_str_mv |
International Journal of Pharmaceutics, v. 603. 1873-3476 0378-5173 10.1016/j.ijpharm.2021.120658 2-s2.0-85105870194 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
International Journal of Pharmaceutics |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.source.none.fl_str_mv |
Scopus reponame:Repositório Institucional da UNESP instname:Universidade Estadual Paulista (UNESP) instacron:UNESP |
instname_str |
Universidade Estadual Paulista (UNESP) |
instacron_str |
UNESP |
institution |
UNESP |
reponame_str |
Repositório Institucional da UNESP |
collection |
Repositório Institucional da UNESP |
repository.name.fl_str_mv |
Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP) |
repository.mail.fl_str_mv |
|
_version_ |
1808129550096269312 |